This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Lawrence Corey, MD; King K. Holmes, MD, PhD
University of Washington Seattle

JAMA. 1980;243(1):29.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

We have several questions concerning the methods and results of the study by Blough and Giuntoli (241:2798, 1979) on the use of 2-deoxy-D-glucose in the treatment of genital herpes simplex virus (HSV). Although the authors claimed to have performed a double-blind, placebo-controlled trial, 36 patients received 2-deoxy-D-glucose, while for "ethical reasons" only 15 received the placebo therapy.

Was a formal randomization design employed, and was this compatible with a double-blind study design? In addition, in evaluating the conditions of patients with first episodes of genital herpes, stratification by serological tests into those with true "primary genital herpes," ie, those who are experiencing their first exposure to HSV and those who have experienced prior HSV type 1 infection, must be performed, because patients with primary genital herpes experience a longer duration of viral shedding (mean, 13.0 days) than those with previous HSV type 1 infection (mean, 7.5 days). . . . [Full Text PDF of this Article]

Footnotes
Edited by John D. Archer, MD, Senior Editor.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?